Abbott 'May Change The Game' in COVID Testing With BinaxNOW, Says Morgan Stanley
August 27, 2020 at 10:26 AM EDT
Morgan Stanley analyst David Lewis raised the firm's price target on Abbott to $112 from $106 and keeps an Overweight rating on the shares.
